Liu Mingyu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liu Mingyu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Natal'YA Zhukova
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - D. Yu. Litvinova
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Svetlana Victorovna Tarasenko
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - A. Yu. Sergeev
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Aalyasir Ayoob Wahhab Fahad1 shared publication
Dymnikov Borisovich
1 shared publication
Latest Publications
- 6 November 2026
- Published by Media Sphere Publishing Group in Russian Journal of Stomatology
- Vol. 19 (3)
Application of platelet-rich fibrin (PRF) to improve tissue regeneration in maxillofacial injuries, including trauma and surgically induced tissue damage. (A systematic review)
Objective. To evaluate the effectiveness of platelet-rich fibrin (PRF) for regeneration of bone, soft tissues, neural structures, and dental tissues in traumatic and surgically induced maxillofacial injuries. Materials and methods. A PRISMA 2020 systematic review was conducted using PubMed, eLIBRARY, Google Scholar, Cochrane Library, and reference lists (2010—2025). Of 377 identified records, 38 underwent full-text assessment and 22 were included in the qualitative synthesis. Results. PRF was associated with improved bone regeneration after mandibular fractures, healing after tooth extraction, peripheral nerve recovery, reduced pain and swelling, and enhanced soft-tissue healing. Case reports also suggest potential benefits in avulsed tooth replantation and regenerative endodontics. Considerable heterogeneity in study design and PRF protocols was noted. Conclusion. PRF is a promising autologous adjunct for maxillofacial tissue injuries, but larger standardized randomized trials are needed.
- 6 November 2026
- Published by Media Sphere Publishing Group in Russian Journal of Stomatology
- Vol. 19 (3)
Application of platelet-rich fibrin (PRF) to improve tissue regeneration in maxillofacial injuries, including trauma and surgically induced tissue damage. (A systematic review)
Objective. To evaluate the effectiveness of platelet-rich fibrin (PRF) for regeneration of bone, soft tissues, neural structures, and dental tissues in traumatic and surgically induced maxillofacial injuries. Materials and methods. A PRISMA 2020 systematic review was conducted using PubMed, eLIBRARY, Google Scholar, Cochrane Library, and reference lists (2010—2025). Of 377 identified records, 38 underwent full-text assessment and 22 were included in the qualitative synthesis. Results. PRF was associated with improved bone regeneration after mandibular fractures, healing after tooth extraction, peripheral nerve recovery, reduced pain and swelling, and enhanced soft-tissue healing. Case reports also suggest potential benefits in avulsed tooth replantation and regenerative endodontics. Considerable heterogeneity in study design and PRF protocols was noted. Conclusion. PRF is a promising autologous adjunct for maxillofacial tissue injuries, but larger standardized randomized trials are needed.
- 29 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Stomatology
- Vol. 19 (2) , 56-62
Risk factors for medication-related osteonecrosis of the jaw in patients receiving bisphosphonates and/or denosumab: a systematic review of the literature
Background. Medication-related osteonecrosis of the jaw (MRONJ) remains a rare but clinically relevant complication of antiresorptive treatment. Its risk is shaped by the interaction of drug exposure, oral inflammatory burden, and systemic comorbidity. Objective. To synthesize evidence on risk factors for MRONJ in patients receiving bisphosphonates and/or denosumab and to derive a practice-oriented prevention algorithm. Material and methods. A PRISMA 2020-oriented systematic review was conducted in PubMed/MEDLINE, Scopus, Web of Science, and eLIBRARY.ru, supplemented by CyberLeninka and hand-searching of reference lists. Guidelines, systematic reviews/meta-analyses, cohort studies, and case-control studies focused on adult patients receiving bisphosphonates and/or denosumab were eligible. Thirty-seven records, including 17 Russian VAK-indexed publications, were included in the qualitative synthesis. Results. The most consistent risk factors were oncology-dose exposure, parenteral high-dose regimens, treatment duration and cumulative exposure, sequential antiresorptive/antiangiogenic therapy, active oral inflammatory disease, tooth extraction and other invasive dental procedures, as well as diabetes, smoking, anemia, and long-term corticosteroid use. Evidence on age, sex, vascular factors, and individual laboratory markers remains heterogeneous. Conclusion. MRONJ risk is multifactorial. The most applicable preventive measures are pre-treatment dental optimization, risk stratification by indication and drug class, scheduled monitoring, and a standardized management algorithm for invasive dental care.
- 29 June 2026
- Published by Media Sphere Publishing Group in Russian Journal of Stomatology
- Vol. 19 (2) , 56-62
Risk factors for medication-related osteonecrosis of the jaw in patients receiving bisphosphonates and/or denosumab: a systematic review of the literature
Background. Medication-related osteonecrosis of the jaw (MRONJ) remains a rare but clinically relevant complication of antiresorptive treatment. Its risk is shaped by the interaction of drug exposure, oral inflammatory burden, and systemic comorbidity. Objective. To synthesize evidence on risk factors for MRONJ in patients receiving bisphosphonates and/or denosumab and to derive a practice-oriented prevention algorithm. Material and methods. A PRISMA 2020-oriented systematic review was conducted in PubMed/MEDLINE, Scopus, Web of Science, and eLIBRARY.ru, supplemented by CyberLeninka and hand-searching of reference lists. Guidelines, systematic reviews/meta-analyses, cohort studies, and case-control studies focused on adult patients receiving bisphosphonates and/or denosumab were eligible. Thirty-seven records, including 17 Russian VAK-indexed publications, were included in the qualitative synthesis. Results. The most consistent risk factors were oncology-dose exposure, parenteral high-dose regimens, treatment duration and cumulative exposure, sequential antiresorptive/antiangiogenic therapy, active oral inflammatory disease, tooth extraction and other invasive dental procedures, as well as diabetes, smoking, anemia, and long-term corticosteroid use. Evidence on age, sex, vascular factors, and individual laboratory markers remains heterogeneous. Conclusion. MRONJ risk is multifactorial. The most applicable preventive measures are pre-treatment dental optimization, risk stratification by indication and drug class, scheduled monitoring, and a standardized management algorithm for invasive dental care.
- Open Access
- 1 April 2026
- Published by Bentham Science Publishers Ltd. in The Open Dentistry Journal
- Vol. 20 (1)
Medication-related Osteonecrosis of the Jaw and Dental Implant: A Case Report
Introduction/Background: The rising use of anti-resorptive agents, including denosumab, for bone metastases has led to an increased incidence of medication-related osteonecrosis of the jaw. This particular case represents an important, but also often overlooked, potential late sequelae that may be seen in cancer patients, which is the failure of a previously well-functioning dental implant years down the line, which may then become a causative factor for MRONJ. Case Presentation: A 70-year-old female patient, a chronic user of high-dose denosumab for metastatic breast carcinoma, presented with pain and infection of the mandibular implant, which was functionally osseointegrated for seven years before the onset of symptoms. The patient was evaluated and was found to have a bony sequestrum containing the implant, meaning the diagnosis was a Stage 2 MRONJ. Conservative management was ineffective; thus, surgical intervention involving sequestrectomy and removal of the implant en bloc was performed. Conclusion: This case of treating the patient also shows us that patients undergoing any treatment with denosumab, who have dental implants, are continuously at risk of late-onset MRONJ and hence need long-term surveillance, and thereby, more emphasis needs to be placed on giving them informed consent for such a lifelong risk of acquiring the disease. Thus, great care must be taken before performing any such surgical procedure. This case also shows that the surgery has been successful in treating the patient, without the need to withdraw any ongoing antiresorptive drugs.
- 1 April 2026
- Published by Bentham Science Publishers Ltd. in The Open Dentistry Journal
- Vol. 20 (1)
Open AccessMedication-related Osteonecrosis of the Jaw and Dental Implant: A Case Report
Introduction/Background: The rising use of anti-resorptive agents, including denosumab, for bone metastases has led to an increased incidence of medication-related osteonecrosis of the jaw. This particular case represents an important, but also often overlooked, potential late sequelae that may be seen in cancer patients, which is the failure of a previously well-functioning dental implant years down the line, which may then become a causative factor for MRONJ. Case Presentation: A 70-year-old female patient, a chronic user of high-dose denosumab for metastatic breast carcinoma, presented with pain and infection of the mandibular implant, which was functionally osseointegrated for seven years before the onset of symptoms. The patient was evaluated and was found to have a bony sequestrum containing the implant, meaning the diagnosis was a Stage 2 MRONJ. Conservative management was ineffective; thus, surgical intervention involving sequestrectomy and removal of the implant en bloc was performed. Conclusion: This case of treating the patient also shows us that patients undergoing any treatment with denosumab, who have dental implants, are continuously at risk of late-onset MRONJ and hence need long-term surveillance, and thereby, more emphasis needs to be placed on giving them informed consent for such a lifelong risk of acquiring the disease. Thus, great care must be taken before performing any such surgical procedure. This case also shows that the surgery has been successful in treating the patient, without the need to withdraw any ongoing antiresorptive drugs.
- Open Access
- 18 March 2026
- Published by Khabadze ZS in Эндодонтия Today
- Vol. 24 (1) , 127-135
Prevention of drug-induced osteonecrosis of the jaw in patients with osteoporosis: clinical recommendations
INTRODUCTION. Drug-induced osteonecrosis of the jaw (MRONJ) is one of the most severe complications of antiresorptive therapy in patients with osteoporosis, significantly impairing the quality of life. Despite the growing awareness of doctors, the frequency of MERS with prolonged use of bisphosphonates or denosumab remains in the range of 0.8–12.0%. The purpose of this work was to develop a comprehensive preventive strategy based on the analysis of risk factors aimed at reducing the incidence of MRONJ in patients with osteoporosis. MATERIALS AND METHODS. A retrospective analysis of the medical records of 267 patients who received antiresorptive therapy at the Yizhida Dental Clinic in Shangqiu (China) from 2019 to 2023 was conducted. Dental status, biochemical markers of bone metabolism, treatment regimens, and concomitant risk factors were assessed. Various preventive approaches were compared. The results show that dental screening and oral sanitation before starting antiresorptive treatment reduces the risk of MERS by 72.6%. RESULTS. Maintaining the level of β-CrossLaps above 150 pg/ml was associated with a 63.8% reduction in risk. Individualized surgical interventions, taking into account risk stratification, reduced the incidence of postoperative complications from 11.1% to 0% (with the combined protocol). The comprehensive preventive model provided a significant reduction in the 4-year cumulative incidence of MRONJ from 7.1% to 1.1%, while the effectiveness of the main antiresorptive therapy was not affected. CONCLUSIONS. The analysis makes it possible to recommend a multi-level prevention system, including dental screening, biomarker monitoring, and surgical tactics adapted to individual risk, as an effective strategy for preventing MERS in patients with osteoporosis.
- 18 March 2026
- Published by Khabadze ZS in Эндодонтия Today
- Vol. 24 (1) , 127-135
Open AccessPrevention of drug-induced osteonecrosis of the jaw in patients with osteoporosis: clinical recommendations
INTRODUCTION. Drug-induced osteonecrosis of the jaw (MRONJ) is one of the most severe complications of antiresorptive therapy in patients with osteoporosis, significantly impairing the quality of life. Despite the growing awareness of doctors, the frequency of MERS with prolonged use of bisphosphonates or denosumab remains in the range of 0.8–12.0%. The purpose of this work was to develop a comprehensive preventive strategy based on the analysis of risk factors aimed at reducing the incidence of MRONJ in patients with osteoporosis. MATERIALS AND METHODS. A retrospective analysis of the medical records of 267 patients who received antiresorptive therapy at the Yizhida Dental Clinic in Shangqiu (China) from 2019 to 2023 was conducted. Dental status, biochemical markers of bone metabolism, treatment regimens, and concomitant risk factors were assessed. Various preventive approaches were compared. The results show that dental screening and oral sanitation before starting antiresorptive treatment reduces the risk of MERS by 72.6%. RESULTS. Maintaining the level of β-CrossLaps above 150 pg/ml was associated with a 63.8% reduction in risk. Individualized surgical interventions, taking into account risk stratification, reduced the incidence of postoperative complications from 11.1% to 0% (with the combined protocol). The comprehensive preventive model provided a significant reduction in the 4-year cumulative incidence of MRONJ from 7.1% to 1.1%, while the effectiveness of the main antiresorptive therapy was not affected. CONCLUSIONS. The analysis makes it possible to recommend a multi-level prevention system, including dental screening, biomarker monitoring, and surgical tactics adapted to individual risk, as an effective strategy for preventing MERS in patients with osteoporosis.